Application of PRISMA Statement: A Status-quo Survey_Chinese Journal of Evidence-Based Medicine

Authors：

 WANGXiao-qin ^1,2 , WEIDang ^1,2 , LIUYa-li ^1,2,3 , WUCai-liang ⁴ , JIKai ⁴ , WEIJin-quan ⁴ ,  YANGKe-hu ^1,2,3

1. Evidence-based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China;
2. Key Laboratory of Evidence-based Medicine and Knowledge Translation of Gansu Province, Lanzhou 730000, China;
3. Chinese GRADE Center, Lanzhou University, Lanzhou 730000, China;
4. First Hospital of Lanzhou University, Lanzhou 730000, China;

Corresponding?author：

YANGKe-hu, Email: yangkh@lzu.edu.cn

Keywords：

PRISMA statement; Reporting guideline; Systematic review; Meta-analysis

DOI：

10.7507/1672-2531.20140187

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To get known of the application of Preferred Items of Systematic Review and Meta Analysis (PRISMA). Methods We searched PubMed, EMbase, The Cochrane Library (Issue 10, 2013), CBM, WanFang Data and CNKI, to collect relevant literature about the application of PRISMA during 2009-2013. Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and then bibliometric analysis was performed using Excel software. Results We finally included 175 papers, including 26 conference abstracts and 149 full texts. The results of bibliometric analysis of full texts showed that, they were published in 118 journals, and PRISMA official website announced that 176 journals endorsed the application of PRISMA. According to study type, there were 111 systematic reviews and meta-analyses (SRs/MAs) for development and reporting, 20 overviews of SRs for reporting quality assessments, 7 versions of PRISMA interpretation, and 11 articles of other kinds. In 131 SRs/MAs as well as overviews, the studies about western medicine accounted for 77.8%, followed by public health (8.4%), and traditional Chinese medicine (4.6%). Conclusion The application of PRISMA statement is still at the first phase and mainly confined to the field of western medicine, which needs more attention and understanding. Thus, it's necessary to interpret and disseminate the PRISMA statement.

Citation： WANGXiao-qin, WEIDang, LIUYa-li, WUCai-liang, JIKai, WEIJin-quan, YANGKe-hu. Application of PRISMA Statement: A Status-quo Survey. Chinese Journal of Evidence-Based Medicine, 2014, 14(9): 1160-1164. doi: 10.7507/1672-2531.20140187 Copy

1.	Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol, 1983, 52(6):C32-C36.
2.	Moher D, Tetzlaff J, Tricco AC, et al. Epidemiology and reporting characteristics of systematic reviews. PLoS Med, 2007, 4(3):e78.
3.	Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day:how will we ever keep up? PLoS Med, 2010, 7(9):e1000326.
4.	The PRISMA Group. History.[2014-2-26]. Available at: http://www.prisma-statement.org/history.htm.
5.	Mulrow CD. The medical review article:State of the science. Ann Intern Med, 1987, 106(3):485-488.
6.	Sacks HS, Berrier J, Reitman D, et al. Meta-analysis of randomized controlled trials. New Engl J Med, 1987, 316 (8):450-455.
7.	Moher D, Cook D J, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials:the QUOROM statement. The Lancet, 1999, 354(9193):1896-1900.
8.	尹森林, 劉雪梅, 何林, 等.對系統評價/Meta分析報告規范的系統評價.中國循證醫學雜志, 2011, 11(8):971-977.
9.	The PRISMA Group. Welcome to the PRISMA Statement website.[2014-2-26]. Available at: http://www.prisma-statement.org/index.htm.
10.	The PRISMA Group. Conceptual Issues in the Evolution from QUOROM to PRISMA. 2014-2-26. Available at: http://www.prisma-statement.org/conceptual.htm.
11.	Moher D, Liberati A, Tetzlaff J, 等.系統綜述和薈萃分析優先報告的條目:PRISMA聲明.中西醫結合學報, 2009, 7(9):889-896.
12.	The PRISMA Group. News.[2014-2-26]. Available at: http://www.prisma-statement.org/news.htm.
13.	Wen J, Ren Y, Wang L, et al. The reporting quality of meta-analyses improves:a random sampling study. J Clin Epidemiol, 2008, 61(8):770-775.
14.	衛茂玲, 劉鳴, 蘇維, 等.中文發表系統評價、Meta分析18年現狀分析.華西醫學, 2007, 22(4):697-698.
15.	陳敏, 何佳, 肖飏, 等.國內期刊發表的中醫藥系統評價/Meta分析的現狀分析.中國循證醫學雜, 2012, 12(12):1526-1530.
16.	張伶俐, 梁毅, 胡蝶, 等.循證藥學定義和文獻的系統評價.中國循證醫學雜志, 2011, 11(1):7-13.
17.	The CONSORT Group. Extensions of the CONSORT Statement.[2014-2-26]. Available at: http://www.consort-statement.org/extensions/.
18.	閔婕, 毛兵, 劉艾然, 等. 《中國循證醫學雜志》發表的中醫藥隨機對照試驗質量評價.中國循證醫學雜志, 2010, 10(3):362-366.

1. Furberg CD. Effect of antiarrhythmic drugs on mortality after myocardial infarction. Am J Cardiol, 1983, 52(6):C32-C36.
2. Moher D, Tetzlaff J, Tricco AC, et al. Epidemiology and reporting characteristics of systematic reviews. PLoS Med, 2007, 4(3):e78.
3. Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day:how will we ever keep up? PLoS Med, 2010, 7(9):e1000326.
4. The PRISMA Group. History.[2014-2-26]. Available at: http://www.prisma-statement.org/history.htm.
5. Mulrow CD. The medical review article:State of the science. Ann Intern Med, 1987, 106(3):485-488.
6. Sacks HS, Berrier J, Reitman D, et al. Meta-analysis of randomized controlled trials. New Engl J Med, 1987, 316 (8):450-455.
7. Moher D, Cook D J, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials:the QUOROM statement. The Lancet, 1999, 354(9193):1896-1900.
8. 尹森林, 劉雪梅, 何林, 等.對系統評價/Meta分析報告規范的系統評價.中國循證醫學雜志, 2011, 11(8):971-977.
9. The PRISMA Group. Welcome to the PRISMA Statement website.[2014-2-26]. Available at: http://www.prisma-statement.org/index.htm.
10. The PRISMA Group. Conceptual Issues in the Evolution from QUOROM to PRISMA. 2014-2-26. Available at: http://www.prisma-statement.org/conceptual.htm.
11. Moher D, Liberati A, Tetzlaff J, 等.系統綜述和薈萃分析優先報告的條目:PRISMA聲明.中西醫結合學報, 2009, 7(9):889-896.
12. The PRISMA Group. News.[2014-2-26]. Available at: http://www.prisma-statement.org/news.htm.
13. Wen J, Ren Y, Wang L, et al. The reporting quality of meta-analyses improves:a random sampling study. J Clin Epidemiol, 2008, 61(8):770-775.
14. 衛茂玲, 劉鳴, 蘇維, 等.中文發表系統評價、Meta分析18年現狀分析.華西醫學, 2007, 22(4):697-698.
15. 陳敏, 何佳, 肖飏, 等.國內期刊發表的中醫藥系統評價/Meta分析的現狀分析.中國循證醫學雜, 2012, 12(12):1526-1530.
16. 張伶俐, 梁毅, 胡蝶, 等.循證藥學定義和文獻的系統評價.中國循證醫學雜志, 2011, 11(1):7-13.
17. The CONSORT Group. Extensions of the CONSORT Statement.[2014-2-26]. Available at: http://www.consort-statement.org/extensions/.
18. 閔婕, 毛兵, 劉艾然, 等. 《中國循證醫學雜志》發表的中醫藥隨機對照試驗質量評價.中國循證醫學雜志, 2010, 10(3):362-366.

Previous Article
Implementation of mvmeta Package of Stata Software in Network Meta-Analysis

Chinese Journal of Evidence-Based Medicine

Application of PRISMA Statement: A Status-quo Survey

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content